$Janux Therapeutics (JANX.US)$ 10% Shareholder RA CAPITAL MANAGEMENT, L.P. purchased 1.2 million shares of common stock on Oct 18, 2024 at an average price of $44.75 for a total value of $53.7 million.
This transaction involves other related parties: RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter and Shah Rajeev M..
The transaction was carried out privately, not on public stock exchanges.
What is statement of changes in beneficial ownership of securities?
It is a requirement under federal securities laws that mandates individuals, including officers, directors, and those who hold more than 10% of any class of a company's securities (collectively known as "insiders"), to report their purchases, sales, and holdings of their company's securities by submitting Forms 3, 4, and 5.